Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price lowered by equities researchers at Royal Bank Of Canada from $14.00 to $13.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 99.85% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Zacks Research cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald raised their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Barclays cut their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 4th. Finally, HC Wainwright upped their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

BioCryst Pharmaceuticals Stock Down 2.5%

BCRX traded down $0.17 during mid-day trading on Friday, reaching $6.51. 713,204 shares of the company traded hands, compared to its average volume of 4,819,386. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The stock has a market capitalization of $1.37 billion, a P/E ratio of -130.10, a P/E/G ratio of 0.36 and a beta of 0.80. The company’s fifty day moving average price is $7.28 and its 200-day moving average price is $7.61.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. BioCryst Pharmaceuticals’s quarterly revenue was up 36.1% on a year-over-year basis. During the same period last year, the firm earned ($0.07) earnings per share. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.10, for a total transaction of $646,128.40. Following the sale, the insider directly owned 416,152 shares of the company’s stock, valued at approximately $2,954,679.20. The trade was a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 183,453 shares of company stock worth $1,330,965 in the last three months. 5.10% of the stock is owned by insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jump Financial LLC boosted its stake in shares of BioCryst Pharmaceuticals by 805.0% during the second quarter. Jump Financial LLC now owns 1,347,112 shares of the biotechnology company’s stock valued at $12,070,000 after purchasing an additional 1,198,263 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in BioCryst Pharmaceuticals by 48.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,584,206 shares of the biotechnology company’s stock valued at $14,194,000 after buying an additional 518,623 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 326.1% in the second quarter. Russell Investments Group Ltd. now owns 440,249 shares of the biotechnology company’s stock worth $3,945,000 after buying an additional 336,920 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after acquiring an additional 4,084,403 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth $1,493,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.